Mayflower Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-13,558
| Closed | -$79.2K | – | 373 |
|
|
2024
Q2 | $79.2K | Buy |
13,558
+192
| +1% | +$1.12K | 0.01% | 349 |
|
|
2024
Q1 | $79.7K | Buy |
13,366
+780
| +6% | +$4.65K | 0.01% | 348 |
|
|
2023
Q4 | $25.4K | Buy |
12,586
+8
| +0.1% | +$16 | ﹤0.01% | 337 |
|
|
2023
Q3 | $21.5K | Sell |
12,578
-8
| -0.1% | -$14 | ﹤0.01% | 333 |
|
|
2023
Q2 | $24.1K | Hold |
12,586
| – | – | ﹤0.01% | 349 |
|
|
2023
Q1 | $21.8K | Sell |
12,586
-37
| -0.3% | -$64 | ﹤0.01% | 345 |
|
|
2022
Q4 | $22.3K | Sell |
12,623
-13
| -0.1% | -$23 | ﹤0.01% | 342 |
|
|
2022
Q3 | $29K | Hold |
12,636
| – | – | ﹤0.01% | 322 |
|
|
2022
Q2 | $28K | Sell |
12,636
-342
| -3% | -$758 | ﹤0.01% | 323 |
|
|
2022
Q1 | $50K | Buy |
+12,978
| New | +$50K | 0.01% | 345 |
|